Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population.
作者信息
Borgetti Scott A, Gross Alan E, Kottler Janey, Patel Kenil, Paek Jamie, Mena Lora Alfredo J, Oikle Diane, Jeffries Delisa, Radosta Jon
机构信息
Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois.
出版信息
Antimicrob Steward Healthc Epidemiol. 2021 Jun 24;1(1):e3. doi: 10.1017/ash.2021.165. eCollection 2021.
Abstract
摘要
相似文献
1
Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population.
Antimicrob Steward Healthc Epidemiol. 2021 Jun 24;1(1):e3. doi: 10.1017/ash.2021.165. eCollection 2021.
2
The Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission from Patients With Undiagnosed Coronavirus Disease 2019 (COVID-19) to Roommates in a Large Academic Medical Center.
Clin Infect Dis. 2022 Mar 23;74(6):1097-1100. doi: 10.1093/cid/ciab564.
3
Incidence rate of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among nurses in coronavirus disease 2019 (COVID-19) units versus non-COVID-19-units at a large academic medical center.
Infect Control Hosp Epidemiol. 2022 Feb;43(2):257-259. doi: 10.1017/ice.2021.352. Epub 2021 Aug 2.
4
Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium.
J Virol. 2020 Jul 16;94(15). doi: 10.1128/JVI.00957-20.
5
Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.
Saudi J Biol Sci. 2022 Apr;29(4):1981-1997. doi: 10.1016/j.sjbs.2021.12.020. Epub 2021 Dec 13.
6
SARS-CoV-2-related outcomes after surgical procedures on SARS-CoV-2-positive patients in a large, urban, safety net medical center.
Surg Open Sci. 2021 Jul;5:10-13. doi: 10.1016/j.sopen.2021.04.001. Epub 2021 May 3.
7
Human and novel coronavirus infections in children: a review.
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
8
Antibody-dependent enhancement of coronavirus.
Int J Infect Dis. 2020 Nov;100:483-489. doi: 10.1016/j.ijid.2020.09.015. Epub 2020 Sep 11.
9
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
10
Severe Acute Respiratory Syndrome by SARS-CoV-2 Infection or Other Etiologic Agents Among Brazilian Indigenous Population: An Observational Study from the First Year of Coronavirus Disease (COVID)-19 Pandemic.
Lancet Reg Health Am. 2022 Apr;8:100177. doi: 10.1016/j.lana.2021.100177. Epub 2022 Jan 7.
引用本文的文献
1
Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities.
Infect Control Hosp Epidemiol. 2023 Oct;44(10):1690-1692. doi: 10.1017/ice.2023.25. Epub 2023 Apr 4.
本文引用的文献
1
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
2
Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.
BMJ. 2020 Nov 11;371:m4362. doi: 10.1136/bmj.m4362.
3
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.
Zotero 插件